Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003380 · ClinicalTrials.gov registry record · Phase 1
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
A Phase 1 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00003380 is a Phase 1 study that was terminated before completion, run by Gynecologic Oncology Group.
The verdict
NCT00003380, a Phase 1 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of liposomal doxorubicin and etoposide in treating patients who have recurrent or persistent ovarian, fallopian tube, or peritoneal cancer.
Interventions
- DRUG etoposide
- DRUG pegylated liposomal doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003380
The ClinicalTrials.gov registry entry for NCT00003380 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which etoposide is the first listed.
NCT00003380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003380 about?
NCT00003380 is a clinical study titled "Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of liposomal doxorubicin and etopo...
What is the current status of trial NCT00003380?
This trial is currently terminated. It is a Phase 1 study. The study started on 1998-05.
What interventions are being tested in trial NCT00003380?
The interventions under investigation include: etoposide (DRUG), pegylated liposomal doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003380?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.